

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/077086-2025>

Award

BH_NonClinical_Pharmacy_Car-T

Barts Health NHS Trust

UK5: Transparency notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2025/S 000-077086

Procurement identifier (OCID): ocds-h6vhtk-05e8d3

Published 26 November 2025, 9:46am

Scope

Reference

C402343

Description

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.

The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products

At the time of writing it is only offered at 8 sites across the UK.

The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.

The price paid to the supplier will be capped at NICE / NHS England approved list prices.

Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products

Supplier

- Bristol Myers Squibb

Contract value

- £2,100,000 excluding VAT
- £2,520,000 including VAT

Above the relevant threshold

Earliest date the contract will be signed

8 December 2025

Contract dates (estimated)

- 8 December 2025 to 5 December 2030
- Possible extension to 7 December 2035
- 10 years

Description of possible extension:

Option to extend contract by a further 5 years

Main procurement category

Services

Options

The right to additional purchases while the contract is valid.

Extension option

CPV classifications

- 33000000 - Medical equipments, pharmaceuticals and personal care products
- 85149000 - Pharmacy services

Other information

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Direct award

Direct award justification

Single supplier - intellectual property or exclusive rights

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.

The products can only be supplied by the the proposed contractor, Bristol Myers Squibb.

Supplier

Bristol Myers Squibb

- Companies House: 02487574

Arc Uxbridge Sanderson Road, New Denham,

Denham

UB8 1DH

United Kingdom

Email: jon.joyce@bms.com

Region: UKJ13 - Buckinghamshire CC

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products

Contracting authority

Barts Health NHS Trust

- Public Procurement Organisation Number: PVTL-5832-LMDG

20 Churchill Place, Canary Wharf

London

E14 5HJ

United Kingdom

Email: oliver.watling@nhs.net

Website: <https://www.bartshealth.nhs.uk>

Region: UKI42 - Tower Hamlets

Organisation type: Public authority - central government